SEARCH · Search PubMed

Results for “STILBAMIDINE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

SourceResearch connectionFrom yearThrough year

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 127 records · Page 7Linked to original sources

PubMed1975

The inhibition of urokinase by aromatic diamidines.

1. Structure-activity relationships have been established for the inhibition of urokinase by aromatic diamidines. In an assay system employing purified urokinase and human plasminogen the most potent inhibitor was found in 4',4''-diamidino-2-hydroxy-1,4-diphenoxybutane which proved 5600 times more active on a molar bases than epsilon-aminocaproic acid (E-ACA). 2. 4',4''-diamidino-2-hydroxy-1,4-diphenoxybutane behaved as a competitive inhibitor of the urokinase catalyzed hydrolysis of N-alpha-acetyl-L-lysine methyl ester. At pH 7.85 and 37 degrees C the K-1 value was determined as 3.18 times 10-6 M which compares with a value of 6.79 times 10-5 M for p-aminobenzamidine and 3.57 times 10-2 M for E-ACA. 3. In two fibrinolytic tests including urokinase as activator the superiority of diamidines over E-ACA was less marked than in the pure plasminogen activation system. This was due to the presence of certain plasma proteins in the fibrinolysis assays which augmented the inhibitory strength of E-ACA. The order of effectiveness of diamidines in the lysis tests was also different from the one in the activation test. In a human fibrin clot lysis test the most active inhibitor was 3',3''-diamidino-2-hydroxy-1,4-diphenoxybutane which was 1700 times more effective on a molar basis than E-ACA. In a human plasma clot lysis test the strongest inhibitor, 2-hydroxy-stilbamidine, was 70 times more powerful than E-ACA.

Amidines↗

PubMed1980

Effects of counterstaining with DNA binding drugs on fluorescent banding patterns of human and mammalian chromosomes.

Pairs of fluorescent A-T specific dyes and nonfluorescent agents with similar or complementary base pair binding specificity were used to analyse the extent to which banding patterns in human chromosomes obtained by fluorescent staining can be modified by counterstaining. By testing a variety of different combinations of drugs, essentially three types of alterations were observed. Enhanced contrast of specific heterochromatic regions was obtained with pentamidine, or netropsin, in conjunction with the fluorescent stains Hoechst 33258, DAPI or DIPI, the resulting banding patterns being similar to that reported for distamycin A plus DAPI (DA-DAPI banding [21]. Uniform quenching of Hoechst 33258, DAPI or DIPI fluorescence was induced by counterstaining with stilbamidine or berenil. The combination of echinomycin with DAPI resulted in an improved contrast of DAPI banding on chromosome arms and pale fluorescence on major autosomal C band regions. In addition, a subdivision of the heterochromatic part of the Y chromosome may be discerned by this latter technique.

Animals↗

PubMed1982

Pulmonary fungal infection. Survey of 159 cases with surgical implications.

A survey of 159 cases of pulmonary fungal disease treated at the Hospital of the University of Mississippi is presented. The fungal diseases encountered were blastomycosis, 75 cases (47%); histoplasmosis, 38 cases (24%); aspergillosis, 17 cases (11%); cryptococcosis, 13 cases (8%); nocardiosis, nine cases (6%); and actinomycosis, seven cases (4%). Coccidioidomycosis is not endemic to Mississippi. Histoplasmosis was probably more common than diagnosed, but clear cytologic evidence or detection of the organisms was the rigid criterion required for diagnosis. Immunosuppressed patients appeared to be especially susceptible to infection by certain of the fungi. Fungal diseases were found to mimic numerous other pulmonary lesions, and specific diagnosis was often long delayed. Seventy-one operations were required for diagnosis or therapy or both, with two deaths. The major pulmonary complications of the several fungal diseases have been reviewed. Pulmonary hemorrhage constituted the major emergency. Amphotericin B was the mainstay of drug therapy, but upon occasion stilbamidine, penicillin, sulfonamides, and other agents were useful in specific circumstances. Accurate diagnosis, appropriate drug therapy, and judicious operative intervention when required will achieve gratifying clinical results in the vast majority of pulmonary fungal diseases.

Actinomycosis↗

PubMed1979

Benzalkonium chloride: selective inhibitor of histamine release induced by compound 48/80 and other polyamines.

Benzalkonium chloride (BAC) is a mixture of quaternary benzyldimethylalkylammonium chlorides which was found to inhibit histamine release induced by polyamines (48/80, ATP, bradykinin, curare, guanethidine, polylysine, polymyxin B, poly-THIQ, protamine, stilbamidine or substance P), but not that caused by antigens, concanavalin A, dextran, lonophores (A23187 or X-537A), enzymes (chymotrypsin or phospholipase C), monoamines (dextromethorphan, meperidine or chlorpromazine) or detergents (decylamine, Triton X-100 or a fire ant venom alkylpiperidine). Inhibition by 1.5 and 3 microgram of BAC per ml caused parallel shifts of the 48/80 dose-response curves to the right with no loss of efficacy, indicating that the antagonism was surmountable. Phospholipase C was partially inhibited by BAC, but Triton X-100 also inhibited phospholipase C (but not 48/80), indicating that the inhibition of phospholipase C by BAC was probably a nonspecific, detergent effect. BAC caused histamine release by itself at concentrations over 5 microgram/ml. Heat inactivation (50 degrees C for 15 min) of the mast cells did not prevent this release, suggesting a lytic mechanism for this action. Structure-activity relations studies on various members of the BAC family for their ability to inhibit 48/80-induced histamine release indicated that benzyldimethyltridecylammonium chloride was the most potent.

Animals↗

PubMed1964